As of 2026-05-10, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -300.09. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 593.28 mil USD. TBPH's TTM EBITDA according to its financial statements is -1.98 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 5.5x - 7.0x | 6.2x |
| Forward P/E multiples | 8.3x - 11.7x | 10.0x |
| Fair Price | 5.27 - 16.83 | 10.20 |
| Upside | -69.0% - -1.1% | -40.0% |
| Date | EV/EBITDA |
| 2026-05-08 | -300.09 |
| 2026-05-07 | -300.35 |
| 2026-05-06 | -298.27 |
| 2026-05-05 | -292.80 |
| 2026-05-04 | -297.49 |
| 2026-05-01 | -294.36 |
| 2026-04-30 | -293.06 |
| 2026-04-29 | -291.24 |
| 2026-04-28 | -293.58 |
| 2026-04-27 | -294.88 |
| 2026-04-24 | -285.77 |
| 2026-04-23 | -281.86 |
| 2026-04-22 | -288.63 |
| 2026-04-21 | -289.94 |
| 2026-04-20 | -292.54 |
| 2026-04-17 | -305.82 |
| 2026-04-16 | -294.10 |
| 2026-04-15 | -290.46 |
| 2026-04-14 | -289.41 |
| 2026-04-13 | -286.81 |
| 2026-04-10 | -282.90 |
| 2026-04-09 | -288.11 |
| 2026-04-08 | -289.41 |
| 2026-04-07 | -288.37 |
| 2026-04-06 | -276.39 |
| 2026-04-02 | -274.31 |
| 2026-04-01 | -269.62 |
| 2026-03-31 | -279.78 |
| 2026-03-30 | -254.51 |
| 2026-03-27 | -249.83 |
| 2026-03-26 | -252.69 |
| 2026-03-25 | -255.30 |
| 2026-03-24 | -245.14 |
| 2026-03-23 | -241.23 |
| 2026-03-20 | -230.29 |
| 2026-03-19 | -221.96 |
| 2026-03-18 | -217.27 |
| 2026-03-17 | -219.61 |
| 2026-03-16 | -219.88 |
| 2026-03-13 | -215.97 |
| 2026-03-12 | -218.83 |
| 2026-03-11 | -216.75 |
| 2026-03-10 | -222.48 |
| 2026-03-09 | -221.70 |
| 2026-03-06 | -210.50 |
| 2026-03-05 | -210.76 |
| 2026-03-04 | -212.97 |
| 2026-03-03 | -220.66 |
| 2026-03-02 | -350.62 |
| 2026-02-27 | -332.39 |